Repligen Closes $1.5 Billion BioLife Deal, Adding Cell Therapy Tools to Waltham Biotech Supplier
Waltham-based Repligen closed its $1.5B BioLife Solutions deal on Oct. 6. Terms, dates, why cell therapy tools matter and what it means for Boston biotech.